The endogenous substrates of brain CYP2D

European Journal of Pharmacology

Volumn 724, Issue 1, 2014, Pages 211-218

  Wang, Xiaoshuang ^a,b   Li, Jie ^a   Dong, Guicheng ^c   Yue, Jiang ^a  

^a WUHAN UNIVERSITY   (China)

^b Puren Hospital of Wuhan City   (China)

^c INNER MONGOLIA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Brain; Cytochrome P450 2D; Endogenous substrates

Indexed keywords

CYTOCHROME P450 2D; CYTOCHROME P450 2D1; CYTOCHROME P450 2D18; CYTOCHROME P450 2D2; CYTOCHROME P450 2D3; CYTOCHROME P450 2D4; CYTOCHROME P450 2D6; ESTROGEN; PROGESTERONE; TESTOSTERONE; TRYPTAMINE; TYRAMINE; UNCLASSIFIED DRUG;

BRAIN METABOLISM; COGNITION; ENZYME REGULATION; ENZYME SUBSTRATE; HORMONE ACTION; HUMAN; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PERSONALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SUICIDAL BEHAVIOR;

BRAIN; CYTOCHROME P450 2D; ENDOGENOUS SUBSTRATES;

ALCOHOL OXIDOREDUCTASES; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BRAIN; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS;

EID: 84892642774     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.12.025     Document Type: Review

References (103)

1. W. Aichhorn, U. Weiss, J. Marksteiner, G. Kemmler, T. Walch, G. Zernig, R. Stelzig-Schoeler, C. Stuppaeck, and C. Geretsegger Influence of age and gender on risperidone plasma concentrations J. Psychopharmacol. 19 2005 395 401
2. M.M. Airaksinen, and I. Kari Beta-carbolines, psychoactive compounds in the mammalian body. Part I: Occurrence, origin and metabolism Med. Biol. 59 1981 21 34
3. M.M. Airaksinen, and I. Kari beta-Carbolines, psychoactive compounds in the mammalian body. Part II: effects Med. Biol. 59 1981 190 211
4. G.D. Anderson, and D.B. Carr Effect of pregnancy on the pharmacokinetics of antihypertensive drugs Clin. Pharmacokinet. 48 2009 159 168
5. L.O. Baum, and H.W. Strobel Regulation of expression of cytochrome P-450 2D mRNA in rat brain with steroid hormones Brain Res. 765 1997 67 73
6. A.F. Bergh, and H.W. Strobel Anatomical distribution of NADPH-cytochrome P450 reductase and cytochrome P4502D forms in rat brain: effects of xenobiotics and sex steroids Mol. Cell Biochem. 162 1996 31 41
7. E. Bromek, A. Haduch, and W.A. Daniel The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: An in vitro study Eur. J. Pharmacol. 626 2010 171 178
8. E. Bromek, A. Haduch, K. Golembiowska, and W.A. Daniel Cytochrome P450 mediates dopamine formation in the brain in vivo J. Neurochem. 118 2011 806 815
9. W.J. Burke The progression of Parkinson disease: a hypothesis Neurology 69 710-711 2007 711
10. R. Cacabelos, R. Martinez, L. Fernandez-Novoa, J.C. Carril, V. Lombardi, I. Carrera, L. Corzo, I. Tellado, J. Leszek, A. McKay, and M. Takeda Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics Int. J. Alzheimers Dis. 2012 2012 518901
11. S.J. Chinta, H.V. Pai, and V. Ravindranath Presence of splice variant forms of cytochrome P4502D1 in rat brain but not in liver Brain Res. Mol. Brain Res. 135 2005 81 92
12. T. Chow, S. Imaoka, T. Hiroi, and Y. Funae Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver Drug Metab. Dispos. 27 1999 188 192
13. C. de Graaf, C. Oostenbrink, P.H. Keizers, T. van der Wijst, A. Jongejan, and N.P. Vermeulen Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking J. Med. Chem. 49 2006 2417 2430
14. C. de Graaf, C. Oostenbrink, P.H. Keizers, B.M. van Vugt-Lussenburg, R.A. van Waterschoot, R.A. Tschirret-Guth, J.N. Commandeur, and N.P. Vermeulen Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6 Curr. Drug. Metab. 8 2007 59 77
15. D.T. Dexter, and P. Jenner Parkinson disease: from pathology to molecular disease mechanisms Free Radic. Biol. Med. 62 2013 132 144
16. L.J. Dickmann, S. Tay, T.D. Senn, H. Zhang, A. Visone, J.D. Unadkat, M.F. Hebert, and N. Isoherranen Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy Biochem. Pharmacol. 75 2008 1677 1687
17. M. Djebaili, Q. Guo, E.H. Pettus, S.W. Hoffman, and D.G. Stein The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats J. Neurotrauma 22 2005 106 118
18. C.J.R. Dunning, J.F. Reyes, J.A. Steiner, and P. Brundin Can Parkinson's disease pathology be propagated from one neuron to another? Prog. Neurobiol. 97 2012 205 219
19. J. Durdiakova, D. Ostatnikova, and P. Celec Testosterone and its metabolites - modulators of brain functions Acta Neurobiol. Exp. (Wars) 71 2011 434 454
20. F. Dutheil, P. Beaune, and M.A. Loriot Xenobiotic metabolizing enzymes in the central nervous system: contribution of cytochrome P450 enzymes in normal and pathological human brain Biochimie 90 2008 426 436
21. F. Dutheil, S. Dauchy, M. Diry, V. Sazdovitch, O. Cloarec, L. Mellottee, I. Bieche, M. Ingelman-Sundberg, J.P. Flinois, I. de Waziers, P. Beaune, X. Decleves, C. Duyckaerts, and M.A. Loriot Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function Drug Metab. Dispos. 37 2009 1528 1538
22. F. Dutheil, A. Jacob, S. Dauchy, P. Beaune, J.M. Scherrmann, X. Decleves, and M.A. Loriot ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders Expert Opin. Drug Metab. Toxicol. 6 2010 1161 1174
23. M. Eichelbaum, M.P. Baur, H.J. Dengler, B.O. Osikowska-Evers, G. Tieves, C. Zekorn, and C. Rittner Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22 Br. J. Clin Pharmacol. 23 1987 455 458
24. A. Elbaz, C. Levecque, J. Clavel, J.S. Vidal, F. Richard, P. Amouyel, A. Alperovitch, M.C. Chartier-Harlin, and C. Tzourio CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease Ann. Neurol. 55 2004 430 434
25. C.S. Ferguson, and R.F. Tyndale Cytochrome P450 enzymes in the brain: emerging evidence of biological significance Trends Pharmacol. Sci. 32 2011 708 714
26. J. Fichna, A. Janecka, J. Costentin, and R.J. Do The endomorphin system and its evolving neurophysiological role Pharmacol. Rev. 59 2007 88 123
27. Y. Funae, W. Kishimoto, T. Cho, T. Niwa, and T. Hiroi CYP2D in the brain Drug Metab. Pharmacokinet. 18 2003 337 349
28. F.J. Gonzalez, T. Matsunaga, K. Nagata, U.A. Meyer, D.W. Nebert, J. Pastewka, C.A. Kozak, J. Gillette, H.V. Gelboin, and J.P. Hardwick Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism DNA 6 1987 149 161
29. I. Gonzalez, E.M. Penas-Lledo, B. Perez, P. Dorado, M. Alvarez, and A. LLerena Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers Pharmacogenomics 9 2008 833 840
30. F.P. Guengerich, G.P. Miller, I.H. Hanna, H. Sato, and M.V. Martin Oxidation of methoxyphenethylamines by cytochrome P450 2D6. Analysis of rate-limiting steps J. Biol. Chem. 277 2002 33711 33719
31. S. Haji-Momenian, J.M. Rieger, T.L. Macdonald, and M.L. Brown Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6 Bioorg. Med. Chem. 11 2003 5545 5554
32. N. Hauptmann, J. Grimsby, J.C. Shih, and E. Cadenas The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA Arch Biochem. Biophys. 335 1996 295 304
33. M.G. Hildebrandt, E.W. Steyerberg, K.B. Stage, J. Passchier, and P. Kragh-Soerensen Are gender differences important for the clinical effects of antidepressants? Am. J. Psychiatry 160 2003 1643 1650
34. T. Hiroi, W. Kishimoto, T. Chow, S. Imaoka, T. Igarashi, and Y. Funae Progesterone oxidation by cytochrome P450 2D isoforms in the brain Endocrinology 142 2001 3901 3908
35. T. Hiroi, S. Imaoka, and Y. Funae Dopamine formation from tyramine by CYP2D6 Biochem. Biophys. Res. Commun. 249 1998 838 843
36. L.S. Hodge, and T.S. Tracy Alterations in drug disposition during pregnancy: implications for drug therapy Expert Opin. Drug Metab. Toxicol. 3 2007 557 571
37. A.S. Horn, and S.R. Snodgrass The occurrence of tryptamine in rat brain and its pharmacological manipulation Br. J. Pharmacol. 47 1973 646P
38. N. Hosono, M. Kato, K. Kiyotani, T. Mushiroda, S. Takata, H. Sato, H. Amitani, Y. Tsuchiya, K. Yamazaki, T. Tsunoda, H. Zembutsu, Y. Nakamura, and M. Kubo CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection Clin. Chem. 55 2009 1546 1554
39. A.V. Juorio, and I.A. Paterson Tryptamine may couple dopaminergic and serotonergic transmission in the brain Gen Pharmacol. 21 1990 613 616
40. J. Jurica, R. Bartecek, A. Zourkova, E. Pindurova, A. Sulcova, T. Kasparek, and O. Zendulka Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice J. Clin. Pharm. Ther. 37 2012 486 490
41. H. Kawashima, and H.W. Strobel cDNA cloning of a novel rat brain cytochrome P450 belonging to the CYP2D subfamily Biochem. Biophys. Res. Commun. 209 1995 535 540
42. W. Kishimoto, T. Hiroi, M. Shiraishi, M. Osada, S. Imaoka, S. Kominami, T. Igarashi, and Y. Funae Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain Endocrinology 145 2004 699 705
43. W.E. Kramer, D.L. Walker, D.J. O'Kane, D.A. Mrazek, P.K. Fisher, B.A. Dukek, J.K. Bruflat, and J.L. Black CYP2D6: novel genomic structures and alleles Pharmacogenet Genomics 19 2009 813 822
44. A.P. Kulkarni Role of biotransformation in conceptal toxicity of drugs and other chemicals Curr. Pharm Des. 7 2001 833 857
45. M.C. Kurth, and J.H. Kurth Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease Am. J. Med. Genet. 48 1993 166 168
46. A.J. Lee, M.X. Cai, P.E. Thomas, A.H. Conney, and B.T. Zhu Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms Endocrinology 144 2003 3382 3398
47. A. Llerena, G. Edman, J. Cobaleda, J. Benitez, D. Schalling, and L. Bertilsson Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6 Acta. Psychiatr. Scand. 87 1993 23 28
48. A. Mann, S. Miksys, A. Lee, D.C. Mash, and R.F. Tyndale Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment Neuropharmacology 55 2008 1147 1155
49. A. Mann, S.L. Miksys, A. Gaedigk, S.J. Kish, D.C. Mash, and R.F. Tyndale The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients Neurobiol. Aging 33 2012 2160 2171
50. A. Mann, and R.F. Tyndale Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells Eur. J. Neurosci. 31 2010 1185 1193
51. K.J. Mantione, P. Cadet, W. Zhu, R.M. Kream, M. Sheehan, G.L. Fricchione, Y. Goumon, T. Esch, and G.B. Stefano Endogenous morphine signaling via nitric oxide regulates the expression of CYP2D6 and COMT: autocrine/paracrine feedback inhibition Addict Biol. 13 2008 118 123
52. C. Martinez, J.A. Agundez, G. Gervasini, R. Martin, and J. Benitez Tryptamine: a possible endogenous substrate for CYP2D6 Pharmacogenetics 7 1997 85 93
53. A. Marzo, and A. Rescigno Pharmacokinetics of endogenous substances: some problems and some solutions Eur. J. Drug Metab. Pharmacokinet. 18 1993 77 88
54. N. Matoh, S. Tanaka, M. Takehashi, M. Banasik, T. Stedeford, E. Masliah, S. Suzuki, Y. Nishimura, and K. Ueda Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells Gene. Expr. 11 2003 117 124
55. S.J. McCann, S.M. Pond, K.M. James, and D.G. Le Couteur The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis J. Neurol. Sci. 153 1997 50 53
56. R.P. Meyer, and M. Gehlhaus A role for CYP in the drug-hormone crosstalk of the brain Expert Opin. Drug Metab. Toxicol. 6 2010 675 687
57. S. Miksys, Y. Rao, E. Hoffmann, D.C. Mash, and R.F. Tyndale Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics J. Neurochem. 82 2002 1376 1387
58. S. Miksys, Y. Rao, E.M. Sellers, M. Kwan, D. Mendis, and R.F. Tyndale Regional and cellular distribution of CYP2D subfamily members in rat brain Xenobiotica 30 2000 547 564
59. S. Miksys, and R.F. Tyndale The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics Drug Metab. Rev. 36 2004 313 333
60. D. Mizuno, T. Hiroi, P. Ng, W. Kishimoto, S. Imaoka, and Y. Funae Regulation of CYP2D expression in rat brain by toluene Osaka City Med. J. 49 2003 49 56
61. K. Monostory, and Z. Dvorak Steroid regulation of drug-metabolizing cytochromes P450 Curr. Drug Metab. 12 2011 154 172
62. D.R. Nelson, L. Koymans, T. Kamataki, J.J. Stegeman, R. Feyereisen, D.J. Waxman, M.R. Waterman, O. Gotoh, M.J. Coon, R.W. Estabrook, I.C. Gunsalus, and D.W. Nebert P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature Pharmacogenetics 6 1996 1 42
63. T. Niwa, T. Hiroi, D. Tsuzuki, S. Yamamoto, S. Narimatsu, T. Fukuda, J. Azuma, and Y. Funae Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6 Brain Res. Mol. Brain Res. 129 2004 117 123
64. T. Niwa, K. Okada, T. Hiroi, S. Imaoka, S. Narimatsu, and Y. Funae Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain Biol. Pharm. Bull. 31 2008 348 351
65. T. Niwa, Y. Yabusaki, K. Honma, N. Matsuo, K. Tatsuta, F. Ishibashi, and M. Katagiri Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones Xenobiotica 28 1998 539 547
66. J. Olah, A.J. Mulholland, and J.N. Harvey Understanding the determinants of selectivity in drug metabolism through modeling of dextromethorphan oxidation by cytochrome P450 Proc. Natl. Acad Sci. USA 108 2011 6050 6055
67. W.M. Pardridge, and L.J. Mietus Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone J. Clin. Invest. 64 1979 145 154
68. E.M. Penas-Lledo, P. Dorado, Z. Aguera, M. Gratacos, X. Estivill, F. Fernandez-Aranda, and A. Llerena High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders Mol. Psychiatry 16 2011 691 692
69. E.M. Penas-Lledo, P. Dorado, Z. Aguera, M. Gratacos, X. Estivill, F. Fernandez-Aranda, and A. Llerena CYP2D6 polymorphism in patients with eating disorders Pharmacogenomics J. 12 2012 173 175
70. E.M. Penas-LLedo, P. Dorado, R. Pacheco, I. Gonzalez, and A. LLerena Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers Pharmacogenomics 10 2009 1111 1120
71. S.R. Philips, B. Rozdilsky, and A.A. Boulton Evidence for the presence of m-tyramine, p-tyramine, tryptamine, and phenylethylamine in the rat brain and several areas of the human brain Biol. Psychiatry 13 1978 51 57
72. S. Prasanthi, M. Vidyavathi, K.V. Prasad, and D.R. Krishna O-demethylation of dextromethorphan using microbial cultures Drug. Metab. Lett. 3 2009 10 14
73. F. Raynaud, and P. Pevet Determination of 5-methoxyindoles in pineal gland and plasma samples by high-performance liquid chromatography with electrochemical detection J. Chromatogr. 564 1991 103 113
74. P. Rowland, F.E. Blaney, M.G. Smyth, J.J. Jones, V.R. Leydon, A.K. Oxbrow, C.J. Lewis, M.G. Tennant, S. Modi, D.S. Eggleston, R.J. Chenery, and A.M. Bridges Crystal structure of human cytochrome P450 2D6 J. Biol. Chem. 281 2006 7614 7622
75. J. Shen, and J. Cao Finite-time synchronization of coupled neural networks via discontinuous controllers Cogn. Neurodyn. 5 2011 373 385
76. I. Siegle, P. Fritz, K. Eckhardt, U.M. Zanger, and M. Eichelbaum Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain Pharmacogenetics 11 2001 237 245
77. U.M. Stamer, E.H. Lee, N.I. Rauers, L. Zhang, M. Kleine-Brueggeney, R. Fimmers, F. Stuber, and F. Musshoff CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care Anesth. Analg. 113 2011 48 54
78. J.C. Stevens, S.A. Marsh, M.J. Zaya, K.J. Regina, K. Divakaran, M. Le, and R.N. Hines Developmental changes in human liver CYP2D6 expression Drug Metab. Dispos. 36 2008 1587 1593
79. J.C. Stingl, C. Esslinger, H. Tost, E. Bilek, P. Kirsch, B. Ohmle, R. Viviani, H. Walter, M. Rietschel, and A. Meyer-Lindenberg Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans Neuroimage 59 2012 2818 2823
80. J.C. Stingl, and R. Viviani CYP2D6 in the brain: impact on suicidality Clin. Pharmacol. Ther. 89 2011 352 353
81. T. Takashima, S. Murase, K. Iwasaki, and K. Shimada Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers Drug Metab. Pharmacokinet. 20 2005 177 182
82. L.K. Teh, and L. Bertilsson Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance Drug Metab. Pharmacokinet. 27 2012 55 67
83. C.M. Thompson, J.H. Capdevila, and H.W. Strobel Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid J. Pharmacol. Exp. Ther. 294 2000 1120 1130
84. T.S. Tracy, R. Venkataramanan, D.D. Glover, and S.N. Caritis Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy Am. J. Obstet Gynecol. 192 2005 633 639
85. J.M. Treluyer, E. Jacqz-Aigrain, F. Alvarez, and T. Cresteil Expression of CYP2D6 in developing human liver Eur. J. Biochem. 202 1991 583 588
86. Y. Tsuchiya, M. Nakajima, and T. Yokoi Cytochrome P450-mediated metabolism of estrogens and its regulation in human Cancer Lett. 227 2005 115 124
87. C.J. van der Horst, and I. Ebels Extraction of pineal and uterine tissue at different pH values: a preliminary report on the occurrence of a few groups of compounds in both tissues Cytobios 29 1980 191 203
88. K. Venkatakrishnan, and R.S. Obach In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude Drug Metab. Dispos. 33 2005 845 852
89. M.M. Verbeek, P.B. Geurtz, M.A. Willemsen, and R.A. Wevers Aromatic L-amino acid decarboxylase enzyme activity in deficient patients and heterozygotes Mol. Genet. Metab. 90 2007 363 369
90. M. Wadelius, E. Darj, G. Frenne, and A. Rane Induction of CYP2D6 in pregnancy Clin. Pharmacol. Ther. 62 1997 400 407
91. B. Wang, L.P. Yang, X.Z. Zhang, S.Q. Huang, M. Bartlam, and S.F. Zhou New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme Drug Metab. Rev. 41 2009 573 643
92. T. Wassenberg, M.A. Willemsen, P.B. Geurtz, M. Lammens, K. Verrijp, M. Wilmer, W.T. Lee, R.A. Wevers, and M.M. Verbeek Urinary dopamine in aromatic L-amino acid decarboxylase deficiency: the unsolved paradox Mol. Genet. Metab. 101 2010 349 356
93. R. Welschen, P. Osman, J. Dullaart, W.J. de Greef, J.T. Uilenbroek, and F.H. de Jong Levels of follicle-stimulating hormone, luteinizing hormone, oestradiol-17 beta and progesterone, and follicular growth in the pseudopregnant rat J. Endocrinol. 64 1975 37 47
94. A. Yu, and R.L. Haining Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab. Dispos. 29 2001 1514 1520
95. A.M. Yu, J.R. Idle, T. Herraiz, A. Kupfer, and F.J. Gonzalez Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase Pharmacogenetics 13 2003 307 319
96. A.M. Yu, J.R. Idle, L.G. Byrd, K.W. Krausz, A. Kupfer, and F.J. Gonzalez Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6 Pharmacogenetics 13 2003 173 181
97. A.M. Yu, C.P. Granvil, R.L. Haining, K.W. Krausz, J. Corchero, A. Kupfer, J.R. Idle, and F.J. Gonzalez The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine J. Pharmacol. Exp. Ther. 304 2003 539 546
98. S. Yubero-Lahoz, R. Pardo, M. Farre, B. O'Mahony, M. Torrens, C. Mustata, C. Perez-Mana, M.L. Carbo, and R. de la Torre Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans Clin. Pharmacokinet. 50 2011 319 329
99. J. Yue, S. Miksys, E. Hoffmann, and R.F. Tyndale Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course J. Psychiatry Neurosci. 33 2008 54 63
100. A.L. Zackrisson, B. Lindblom, and J. Ahlner High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases Clin. Pharmacol. Ther. 88 2010 354 359
101. P. Zheng Neuroactive steroid regulation of neurotransmitter release in the CNS: action, mechanism and possible significance Prog. Neurobiol. 89 2009 134 152
102. S.F. Zhou, J.P. Liu, and X.S. Lai Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development Curr. Med. Chem. 16 2009 2661 2805
103. W. Zhu CYP2D6: a key enzyme in morphine synthesis in animals Med. Sci. Monit. 14 2008 C15 C18